Zoloft Birth Defects Lawsuit Update: Latest Developments in Pennsylvania Zoloft MDL

By | Antidepressant, Pharmaceutical litigation, Uncategorized, Zoloft

SSRI Antidpressant Zoloft Birth Defects LitigationThe latest development to come out of the Zoloft birth defects multidistrict litigation (MDL) in the U.S. District Court for the Eastern District of Pennsylvania involves a back and forth between the plaintiffs and the federal judge handling the MDL. Their discussion involves discovery pool and trial pool case selections.

U.S. District Judge Cynthia M. Rufe is presiding over the Zoloft MDL. In late August, she submitted a trial pool selection guideline. In early September, the plaintiffs filed an objection of Judge Rufe’s selection guidelines, taking issue with the defendants’ ability to remove cases from the discovery pool.

The plaintiffs requested that Judge Rufe update her protocol so that the defendants are unable to remove, or strike, cases from the discovery pool submitted by the same plaintiffs’ legal counsel. The plaintiffs made this request on the basis of maintaining a variety of cases in the initial discovery pool, especially as it pertains to the plaintiffs’ legal counsel.

In the court document about this matter, Judge Rufe stated that the selection process for the discovery and trial pools should not involve reference to the plaintiffs’ legal counsel, as this does not necessarily provide a representative case.

The goal in selecting cases for the discovery and trial pools is to find a representative case suitable for a bellwether trial that supports an efficient legal process, and will aid in post-trial settlement.

Ultimately, Judge Rufe came to the conclusion that the defendants cannot remove two cases from the discovery pool whose plaintiffs are represented by the same legal counsel.

Carey Danis & Lowe Zoloft birth defects lawyers are keeping a watchful eye on the Zoloft MDL as it inches closer and closer to the bellwether trial process. Above all, the multidistrict litigation process makes for an efficient legal process. In regards to the most recent court filing in the Zoloft birth defects MDL, Carey Danis & Lowe hopes that the latest ruling is in keeping with this core purpose.

Carey Danis & Lowe is currently accepting Zoloft birth defects cases. Contact Carey Danis & Lowe today for a free legal consultation about your case, and to determine if you and your family are be eligible for compensation. Our Zoloft attorneys can also assist in filing Zoloft birth defects lawsuits.

If you have questions about Zoloft birth defects, voice your questions and concerns to one of our on-staff nurses.

Share your Zoloft birth defects story with Carey Danis & Lowe by calling 800.721.2519, or by submitting a personal injury claim form.

The Injurious Link Between SSRI Antidepressants and Birth Defects

By | Antidepressant, Pharmaceutical litigation, Uncategorized

Published September 13, 2012 on Carey & Danis

The Injurious Link Between SSRI Antidepressants and Birth DefectsA grave conundrum is presented to women who suffer from depression during pregnancy. There are significant mental and physical health issues that must be considered in regards to medicating with a selective serotonin re-uptake inhibitor (SSRI) antidepressant such as Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac while pregnant. Ending use of an SSRI antidepressant during pregnancy poses a risk to the mother’s mental health as well as to the unborn child, depending on when discontinuance of the medication occurs.

If an SSRI antidepressant was taken by the pregnant mother into the third trimester, it has been discovered that these antidepressant medications leach through the placental sack, thus exposing the unborn child to the drugs, often causing a chemical attachment resulting in withdrawal upon the child’s birth or the mother’s sudden termination of SSRI use.Signs of withdrawal in the newborn child are irritable mood, breathing complications, trembling, feeding problems, and hypoglycemia.

In recognition of these withdrawal symptoms in newborn children, the U.S. Food and Drug Administration (FDA) in 2004 released a warning in regards to the use of SSRI antidepressants by pregnant women in their third trimester. In their statement, the FDA made the recommendation that pregnant women medicating with an SSRI antidepressant be placed on a schedule which over time would gradually lower their dosage of an antidepressant.

Though this FDA warning and recommendation was targeted at the prevention of withdrawal symptoms in the newborn child, such near termination of SSRI antidepressant use by the pregnant mother was seen to cause serious mental health issues including a severe episode of postpartum depression. Drug withdrawal is not the only source of suffering inflicted on an unborn child exposed to SSRI antidepressants.

Epidemiology magazine examined in their May 2012 issue a recent study on the health of pregnant mothers using SSRI antidepressants. The study found that there is a significant link between the use of an SSRI antidepressant and pre-term delivery. In this specific study led by the Yale School of Public Health, the SSRI under examination was Paxil. Use of Paxil and other SSRI antidepressants while pregnant have also been linked to a number of other birth defects that cause an undue amount of suffering for a newborn child. These SSRI-linked birth defects include Persistent Pulmonary Hypertension of the Newborn (PPHN), omphalocele, craniosynostosis, atrial septal defects, and ventricular septal defects.

If an SSRI antidepressant was used during pregnancy and a newborn child suffered from a birth defect, compensation for such unfair suffering is due. Contact a knowledgeable pharmaceutical product liability litigation attorney at Carey Danis & Lowe for more information about filing a lawsuit against the manufacturers of Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac.